In contrast to the JAK2V617F mutation, which is a single amino acid change, mutant CALR protein represents a large neoantigen that is expressed on the cell surface, and therefore is an attractive target for tumour‐specific immunotherapy in patients with mutCALR‐driven MPN. This evidence concerns the gene CALR and myeloproliferative disorder.